Literature DB >> 9563168

Sedative and analgesic effects of medetomidine in beagle dogs infected and uninfected with heartworm.

C S Venugopalan1, E P Holmes, M P Crawford, M J Kearney, V Fucci.   

Abstract

The sedative and analgesic effects of medetomidine were evaluated in heartworm-infected (HW+) and uninfected (HW-) beagle dogs by intravenous (IV) and intramuscular (IM) administration of 30 micrograms/kg and 40 micrograms/kg doses, respectively. Posture, response to noise and the pedal reflex were monitored. A procedure for mock radiographic positioning was performed to evaluate its overall clinical use. Observation times were 0, 15, 30, 60, 90, 120 and 180 min. In addition, the times from injection until the dog could not stand on its feet (down time), from lateral to sternal recumbency (sternal recumbency time), and from sternal recumbency to rising again (rising time) were also noted. Medetomidine produced rapid sedation and analgesia by both routes. Down times for the IM and IV routes were similar, which verified the manufacturer's recommended doses. The HW+ dogs had shorter down times, probably owing to increased blood flow to the brain caused by adrenergic alpha-2 activity. Sternal recumbency and rising times did not differ between the groups, suggesting a similar metabolism. Sedation and analgesia were adequate for performing the procedure in all dogs. HW- dogs showed less resistance to handling during the procedure than HW+ dogs. Overall, medetomidine seems to be a suitable agent for short-term chemical restraint in dogs, even with subclinical heartworm infestation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563168     DOI: 10.1023/a:1006075312688

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  26 in total

1.  Clinical comparison of medetomidine with xylazine/l-methadone in dogs.

Authors:  S Kramer; I Nolte; W Jöchle
Journal:  Vet Rec       Date:  1996-02-10       Impact factor: 2.695

Review 2.  An introduction to the pharmacology of alpha 2-adrenoceptors in the central nervous system.

Authors:  M Scheinin; E MacDonald
Journal:  Acta Vet Scand Suppl       Date:  1989

3.  Cardiovascular effects of detomidine, a new alpha 2-adrenoceptor agonist, in the conscious pony.

Authors:  R D Sarazan; W A Starke; G F Krause; H E Garner
Journal:  J Vet Pharmacol Ther       Date:  1989-12       Impact factor: 1.786

4.  Studies to determine the optimal dose of medetomidine for the dog.

Authors:  R L Hamlin; L S Bednarski
Journal:  Acta Vet Scand Suppl       Date:  1989

Review 5.  The clinical efficacy of medetomidine.

Authors:  T Vähä-Vahe
Journal:  Acta Vet Scand Suppl       Date:  1989

Review 6.  Antinociception induced by alpha-2-adrenoceptor agonists, with special emphasis on medetomidine studies.

Authors:  A Pertovaara
Journal:  Prog Neurobiol       Date:  1993-06       Impact factor: 11.685

7.  Sedative and analgesic effects of medetomidine in dogs.

Authors:  O Vainio; T Vähä-Vahe; L Palmu
Journal:  J Vet Pharmacol Ther       Date:  1989-06       Impact factor: 1.786

8.  Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes.

Authors:  S Z Langer; N Duval; R Massingham
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

9.  Medetomidine, an alpha 2-agonist, alleviates post-thoracotomy pain in dogs.

Authors:  O Vainio; M Ojala
Journal:  Lab Anim       Date:  1994-10       Impact factor: 2.471

10.  Spinal potentiation and supraspinal additivity in the antinociceptive interaction between systemically administered alpha 2-adrenoceptor agonist and cocaine in the rat.

Authors:  A Pertovaara; M M Hämäläinen
Journal:  Anesth Analg       Date:  1994-08       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.